Interim results from EMPRISE phase III trial of Jardiance show reduced risk of heart failure in Type 2 diabetes with CV disease.- Boehringer + Eli Lilly

A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance (empagliflozin), from Boehringer and Eli Lilly, was associated with a decreased risk of hospitalisation for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists. The interim analysis included 190,000 adults in the US with type 2 diabetes with and without cardiovascular disease.

In this new interim analysis, empagliflozin was associated with a reduction in risk of hospitalisation for heart failure of 41 percent compared with DPP-4 inhibitors and of 17 percent compared with GLP-1 receptor agonists. Risk for non-fatal atherosclerotic cardiovascular events � defined as non-fatal heart attack or stroke, hospitalisation for unstable angina or coronary revascularisation � was similar for those treated with empagliflozin (14.6 events per 1,000 patient-years) compared with DPP-4 inhibitors (17.6 events per 1,000 patient-years). The risk was also similar for those treated with empagliflozin (14.2 events per 1,000 patient-years) compared with GLP-1 receptor agonists (14.8 events per 1,000 patient-years).

In a second interim analysis of EMPRISE, which included more than 45,000 patients, empagliflozin was associated with a significant reduction in all-cause hospitalisations, emergency department visits and physician�s office visits compared with DPP-4 inhibitors. The results were shared at the American Heart Association Scientific Sessions 2019.